Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
Intergroup Randomized Phase II Four Arm Study In Patients =/>60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab + Bendamustine Followed By Rituximab Consolidation (RB-R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R); Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR); or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-LR).
Closed to Accrual with Ongoing Follow-up
Chemotherapy: Systemic, Immunomodulator, Immunotherapy
Defintions of terms and FAQ about clinical trials.
Anil Tulpule, M.D.
Other Trial Staff:
Christine Duran, D.M., Ibrahim Syed, Coordinator, Melissa Peralta, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N., Donna Fernando, R.N.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.